A patient in Japan has become the first person in the world to receive a stem-cell treatment for Parkinson’s disease outside a clinical trial. The treatment was given at Kyoto University Hospital during October, and it was announced by the Japanese drugmaker Sumitomo Pharma in an earnings statement on Friday. The company did not share details about the patient, or describe how the person is responding so far, but the procedure itself marks a clear change: a therapy tested in a small trial is now being used in ordinary clinical care, following conditional approval in Japan.
The treatment is built around induced pluripotent stem cells, usually shortened to iPS cells. These are adult cells that scientists reprogramme in a laboratory so that they return to a much earlier, more flexible state, from which they can be guided to become many different kinds of cell in the body. In this case, healthy donor cells are turned into precursor cells that can develop into the brain cells that make dopamine, the chemical messenger that helps control smooth, coordinated movement. Those dopamine-making cells are the ones gradually lost in Parkinson’s disease, and replacing them is the central idea behind the new approach.
Parkinson’s is a long-term and progressive disorder of the nervous system that damages the brain’s ability to control movement. Its best-known signs are tremor, stiffness, slowness of movement and difficulty with balance, and as it advances it can also affect speech, swallowing, mood and sleep. More than ten million people around the world are thought to be living with the condition, according to the Parkinson’s Foundation. Existing medicines can ease symptoms for a time, often by replacing or mimicking dopamine, but they do not stop the underlying loss of brain cells, and their benefit can fade or become uneven as the disease progresses. That gap is why a treatment that aims to restore the missing cells has attracted so much attention.
The road to this first treatment began with a clinical trial in which seven patients, aged between fifty and sixty-nine, received the experimental therapy. Each patient had either five million or ten million cells implanted on both sides of the brain, and the participants were then watched closely for two years. Researchers found no major adverse effects during that period, and four of the seven patients showed improvements in their symptoms. Those results were encouraging, but they were also limited: seven people is a very small group, two years is a short time for a lifelong condition, and improvement in four patients does not yet prove how well, or for how long, the treatment will work in a wider population.
Japanese regulators gave the therapy conditional approval in March, after that trial. Conditional approval is a middle path used for some advanced medical treatments: it allows a therapy to be used while more evidence about its safety and effectiveness is still being gathered, rather than waiting for every long-term question to be answered first. It is not the same as full approval, and it comes with the expectation that patients will continue to be followed and that further data will be collected. According to Japanese media reports, the therapy could receive full approval if its safety and effectiveness are confirmed over the next seven years, a long horizon that shows why this first transplant is a beginning, not a verdict.
Sumitomo Pharma developed the therapy in collaboration with Dr Jun Takahashi at Kyoto University, and it is known by the name Amchepry, also called raguneprocel. It is described as the world’s first treatment for Parkinson’s disease based on induced pluripotent stem cells. The company now plans to carry out transplants in twenty to thirty patients by March 2029, a deliberately modest pace that allows doctors to watch for complications, refine the procedure, and learn which patients are most likely to benefit before it is offered more widely. A clinical trial is also under way in the United States, and Japan’s wider role in regenerative medicine was underlined only a month earlier, when a hospital in Osaka carried out what was reported as the world’s first operation using sheets of heart muscle made from iPS cells, a therapy that also received conditional approval in March.
For patients and families, the news will therefore carry hope and caution at the same time. Hope, because a disease long managed rather than treated at its root may finally have a therapy that addresses the cause. Caution, because one transplant, announced without patient details, cannot tell anyone whether the treatment is safe over decades, whether its benefits last, or whether it will be affordable and available beyond a small number of specialist centres. Brain surgery is itself a serious undertaking, and the implanted cells must survive, integrate with surrounding tissue and keep working for years without growing in an uncontrolled way. For now, the Kyoto transplant does not cure Parkinson’s, but after decades in which care meant easing symptoms while the disease quietly advanced, a treatment that tries to replace what has been lost has moved from the laboratory into a hospital ward.
